Plasma Protein Therapeutics

Plasma Protein Therapeutics

Global Plasma Protein Therapeutics Market to Reach US$42.7 Billion by 2030

The global market for Plasma Protein Therapeutics estimated at US$30.8 Billion in the year 2023, is expected to reach US$42.7 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. Albumin, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$9.3 Billion by the end of the analysis period. Growth in the Plasma Derived Factor Viii segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.4 Billion While China is Forecast to Grow at 4.6% CAGR

The Plasma Protein Therapeutics market in the U.S. is estimated at US$8.4 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.8 Billion by the year 2030 trailing a CAGR of 4.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Plasma Protein Therapeutics Market - Key Trends & Drivers Summarized

Why Is the Plasma Protein Therapeutics Market Emerging as a Vital Segment in Chronic Disease Management and Immunotherapy?

The plasma protein therapeutics market is emerging as a vital segment in chronic disease management and immunotherapy due to the unique therapeutic potential of plasma-derived products in treating a broad spectrum of life-threatening conditions. Plasma protein therapeutics are derived from human plasma and include products such as immunoglobulins, coagulation factors, albumin, and protease inhibitors. These therapies are used to treat a variety of rare and chronic conditions, including primary immunodeficiency (PID), hemophilia, chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary angioedema (HAE), and alpha-1 antitrypsin deficiency. The ability of plasma protein therapeutics to replace missing or deficient proteins, modulate immune responses, and improve overall health outcomes makes them indispensable in managing complex and rare diseases that often have limited treatment options.

The increasing prevalence of chronic diseases, rare genetic disorders, and autoimmune conditions is driving demand for plasma protein therapeutics globally. The rise in the number of patients diagnosed with conditions such as immunodeficiency disorders and hemophilia, coupled with growing awareness of these diseases, is leading to greater adoption of plasma-derived products. The improved understanding of plasma protein functions and the role they play in various physiological processes is also expanding their therapeutic applications beyond traditional indications. As healthcare providers and patients recognize the benefits of plasma protein therapies in improving quality of life and reducing disease burden, the plasma protein therapeutics market is expected to witness significant growth, making it a critical component of modern healthcare.

How Are Technological Advancements and Emerging Therapies Transforming the Plasma Protein Therapeutics Market?

Technological advancements and emerging therapies are transforming the plasma protein therapeutics market by enabling the development of high-purity, safe, and efficacious products that cater to the evolving needs of patients with complex medical conditions. One of the most significant innovations in this space is the use of advanced fractionation technologies and purification methods to produce plasma-derived therapies with enhanced safety profiles and reduced risk of pathogen transmission. Fractionation techniques such as chromatography and filtration are being optimized to isolate specific plasma proteins with higher yields and purity, ensuring that final products are free from contaminants and suitable for use in vulnerable patient populations, including those with compromised immune systems.

The introduction of recombinant technologies is also revolutionizing the plasma protein therapeutics market. Recombinant plasma protein therapies, which are produced using genetic engineering techniques, offer an alternative to plasma-derived products by eliminating the need for human plasma as a raw material. These therapies, such as recombinant coagulation factors for hemophilia, provide a consistent and sustainable supply of proteins that are structurally identical to their natural counterparts, reducing the risk of supply shortages and immunogenic reactions. Recombinant products are gaining traction in the market due to their safety profile, scalability, and potential to address the limitations of plasma-derived therapies.

The development of extended half-life (EHL) products is another transformative trend in the plasma protein therapeutics market. EHL products, such as factor VIII and factor IX concentrates with prolonged activity, reduce the frequency of dosing required for patients with hemophilia, improving treatment adherence and quality of life. These products are designed by modifying the protein structure or adding fusion proteins to delay clearance from the bloodstream, allowing for less frequent administration without compromising efficacy. The availability of EHL products is reducing the treatment burden for patients and enabling more effective management of chronic conditions, supporting the adoption of these therapies in clinical practice.

Moreover, the use of gene therapies and RNA-based treatments is emerging as a promising approach to address the underlying genetic causes of conditions such as hemophilia and alpha-1 antitrypsin deficiency. Gene therapies aim to provide a one-time, long-term solution by delivering functional copies of defective genes to restore normal protein production. In hemophilia, gene therapies such as adeno-associated virus (AAV)-based vectors are being developed to deliver the genes for factor VIII or factor IX, potentially reducing or eliminating the need for regular plasma protein infusions. RNA-based therapies, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA), are being explored to modulate gene expression and correct protein deficiencies at the molecular level. These cutting-edge therapies are expanding the therapeutic landscape for plasma protein deficiencies and providing new avenues for treatment.

The increasing use of digital health technologies is further transforming the plasma protein therapeutics market. Digital platforms, wearable devices, and mobile applications are being used to monitor patient adherence, track therapy effectiveness, and provide real-time data on treatment outcomes. These technologies support personalized treatment plans, facilitate remote patient management, and enhance communication between patients and healthcare providers. Digital health solutions are particularly valuable for patients receiving long-term therapies, as they provide insights into treatment response and help identify areas for optimization. As these technological advancements and emerging therapies continue to evolve, they are making plasma protein therapeutics more accessible, effective, and tailored to the needs of individual patients.

What Role Do Market Dynamics and Industry Trends Play in Shaping the Adoption of Plasma Protein Therapeutics?

Market dynamics and industry trends play a pivotal role in shaping the adoption of plasma protein therapeutics as healthcare providers, patients, and industry stakeholders respond to evolving treatment needs, regulatory changes, and supply chain challenges. The growing demand for plasma protein therapies is driven by several factors, including the rising incidence of chronic diseases and the increasing need for targeted therapies that can address the specific requirements of rare disease patients. The expansion of patient populations eligible for plasma protein therapies, driven by improved diagnosis and screening programs, is supporting the adoption of these products in clinical practice. For example, newborn screening programs for conditions such as severe combined immunodeficiency (SCID) and alpha-1 antitrypsin deficiency are enabling early diagnosis and timely intervention with plasma protein therapies.

The emphasis on improving treatment adherence and patient outcomes is also influencing the adoption of plasma protein therapeutics. Healthcare providers are increasingly focused on optimizing treatment regimens to enhance patient quality of life and reduce healthcare costs associated with hospitalizations and complications. The use of extended half-life products, home infusion therapies, and personalized treatment plans is supporting better adherence and long-term outcomes. The availability of patient support programs, educational resources, and nursing services is further facilitating the adoption of plasma protein therapies by helping patients manage their conditions effectively and stay engaged with their treatment plans.

The impact of regulatory changes and the need for compliance with stringent safety and quality standards are also shaping the market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) have established comprehensive guidelines for the production, testing, and distribution of plasma protein therapies. These regulations are designed to ensure that plasma-derived products are free from pathogens, meet purity and potency standards, and are manufactured using validated processes. The implementation of good manufacturing practices (GMP) and adherence to international standards such as the Plasma Protein Therapeutics Association (PPTA) guidelines are critical for maintaining product safety and efficacy. Compliance with these regulations is essential for gaining market approval and ensuring patient safety, influencing the adoption of plasma protein therapies in various regions.

The role of health insurance and reimbursement policies is also crucial in determining access to plasma protein therapies. Given the high cost of plasma-derived and recombinant therapies, reimbursement coverage is essential for ensuring that patients can afford these life-saving treatments. Many countries have established reimbursement policies and insurance coverage for plasma protein therapies, particularly for rare and orphan conditions. The inclusion of these treatments in national formularies and reimbursement lists is reducing the financial burden on patients and encouraging greater use of plasma protein therapies. The availability of patient assistance programs, co-pay support, and specialty pharmacy services is further supporting patient access and adherence to treatment.

The increasing collaboration between pharmaceutical companies, patient advocacy groups, and healthcare providers is also shaping the adoption of plasma protein therapies. Patient advocacy organizations play a key role in raising awareness, providing education, and advocating for better access to treatment. These organizations work closely with industry stakeholders to support research initiatives, provide input on clinical trial design, and facilitate the inclusion of patient perspectives in regulatory decisions. The collaboration between patient groups and pharmaceutical companies is driving the development of patient-centric therapies, improving the quality of care, and supporting the adoption of plasma protein therapeutics in the global healthcare community.

What Factors Are Driving the Growth of the Global Plasma Protein Therapeutics Market?

The growth in the global plasma protein therapeutics market is driven by several factors, including the rising prevalence of chronic diseases and rare genetic disorders, the increasing adoption of plasma protein therapies, and ongoing advancements in therapeutic technologies. One of the primary growth drivers is the rising prevalence of conditions such as primary immunodeficiency (PID), hemophilia, chronic inflammatory demyelinating polyneuropathy (CIDP), and alpha-1 antitrypsin deficiency. These disorders often require lifelong management with plasma-derived therapies to replace missing or deficient proteins, modulate the immune system, and prevent disease complications. The growing number of patients diagnosed with these conditions, coupled with increased awareness and improved diagnostic capabilities, is driving demand for plasma protein therapeutics.

The increasing adoption of plasma protein therapies is another key factor contributing to market growth. As healthcare providers and patients become more aware of the benefits of plasma protein therapies in managing complex and chronic conditions, the use of these products is expanding across various therapeutic areas. The availability of a wide range of plasma-derived and recombinant products, including immunoglobulins, coagulation factors, and C1-inhibitors, is providing healthcare providers with more options for treating patients and optimizing outcomes. The adoption of these therapies is being supported by clinical guidelines and treatment protocols that recommend plasma protein therapies as the standard of care for certain conditions, further boosting their use in clinical practice.

Ongoing advancements in therapeutic technologies are further supporting the growth of the plasma protein therapeutics market. The development of recombinant products, extended half-life therapies, and novel therapeutic agents is expanding the range of available options for patients and improving treatment efficacy and safety. These advancements are enabling more personalized and convenient treatment regimens, reducing the frequency of administration, and enhancing patient adherence and quality of life. The increasing adoption of home-based therapies and self-administration kits is also making it easier for patients to manage their conditions independently, supporting long-term treatment success.

Moreover, the growing focus on research and development (R&D) and the introduction of new therapeutic agents are creating new opportunities for market growth. Pharmaceutical companies are investing in the development of innovative therapies, such as gene therapies and monoclonal antibodies, to provide more effective and long-lasting solutions for plasma protein deficiencies. Clinical trials for novel agents targeting specific pathways involved in disease pathogenesis are providing new insights into the conditions and expanding the therapeutic landscape. The approval and commercialization of new therapies are increasing competition in the market and providing patients with more options for managing their condition.

Additionally, the expansion of treatment indications and the inclusion of pediatric and adolescent populations in clinical trials are contributing to market growth. The approval of plasma protein therapies for use in younger patients is providing new treatment options for pediatric patients with conditions such as hemophilia and primary immunodeficiency. The focus on expanding access to treatment across different age groups and patient populations is supporting the growth of the plasma protein therapeutics market.

Furthermore, the impact of the COVID-19 pandemic has highlighted the importance of ensuring access to essential medications for patients with chronic and rare diseases. The pandemic has underscored the need for robust supply chains, reliable plasma collection, and uninterrupted access to plasma protein therapies. The increased focus on supply chain resilience and patient-centric care is expected to influence the future development and adoption of plasma protein therapeutics. As these factors converge, the global plasma protein therapeutics market is poised for robust growth, driven by technological advancements, expanding treatment options, and the increasing emphasis on improving patient outcomes and quality of life for individuals with chronic and rare conditions.

Select Competitors (Total 42 Featured) -

• Bayer AG
• Biotest AG
• CSL Behring
• Grifols SA
• Kedrion SpA
• Octapharma AG
• Shire PLC

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.